|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
|
22798288 |
2012 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis.
|
12460919 |
2002 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although >90% of BRAF mutations in melanoma involve codon 599 (57 of 60), 8 of 9 BRAF mutations reported to date in NSCLC are non-V599 (89%; P < 10(-7)), strongly suggesting that BRAF mutations in NSCLC are qualitatively different from those in melanoma; thus, there may be therapeutic differences between lung cancer and melanoma in response to RAF inhibitors.
|
12460918 |
2002 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis.
|
12460919 |
2002 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
We sought to determine the frequency of BRAF mutations in human lung cancer pathogenesis.
|
12460919 |
2002 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
|
31711466 |
2019 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
|
19238210 |
2009 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
|
30224342 |
2019 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
|
24035431 |
2013 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Consistent with earlier reports, our results show that KRAS and BRAF mutation frequencies in colorectal cancer were 44.3% and 13.0%, respectively, while EGFR mutations were detected in 11.1% of the lung cancer specimens.
|
21943394 |
2011 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.
|
28203297 |
2017 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
|
22649091 |
2012 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
|
29723688 |
2018 |
|
Carcinoma of lung
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer.
|
23524406 |
2013 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These data, together with the nonoverlapping pattern of EGFR and BRAF mutations in human lung cancer, suggest that these lesions define distinct clinical entities whose treatment should be guided by prospective real-time genotyping.
|
19010912 |
2008 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E is an emerging drug target in lung cancer, but the clinical significance of non-V600 BRAF mutations in lung cancer and other malignancies is less clear.
|
24035431 |
2013 |
|
Carcinoma of lung
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Recent evidence shows that BRAF-activated non-coding RNA (BANCR) acts as a critical role in the proliferation and metastasis in malignant melanoma and lung cancer; however, little is known about the significance of lncRNA BANCR in retinoblastoma.
|
25894373 |
2015 |
|
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
|
24550319 |
2014 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations.
|
25153497 |
2015 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
BRAF mutated lung cancer is a genetically distinct subtype that occurs in 2-5% of non-small cell lung carcinomas (NSCLC).
|
28625649 |
2017 |
|
Carcinoma of lung
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The incidence of BRAF mutations other than V600E is significantly higher in lung cancer than in melanoma.
|
21483012 |
2011 |
|
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
A group of thoracic oncology experts in the field of thoracic oncology met to describe the standard for biomarker testing for lung cancer in the Canadian context, focusing on evidence-based recommendations for standard-of-care testing for <i>EGFR</i>, anaplastic lymphoma kinase (<i>ALK</i>), <i>ROS1</i>, <i>BRAF V600</i> and programmed death-ligand (PD-L1) at the time of diagnosis of advanced disease and <i>EGFR T790M</i> upon progression.
|
29507487 |
2018 |
|
Carcinoma of lung
|
0.700 |
Biomarker
|
disease |
BEFREE |
One of our predicted biomarker pairs, a mutation in the BRAF gene and upregulated expression of the PIM1 gene, was experimentally validated to benefit from a therapy combining BRAF inhibitor and PIM1 inhibitor in lung cancer.
|
26916442 |
2016 |